|
GM-CSF Clinical Trials
5 actively recruiting trials across 3 locations
Also known as: Granulocyte-Macrophage Colony-Stimulating Factor, Recombinant Human Granulocyte/Macrophage Colony-stimulating Factor, Sargramostim
Pipeline
Phase 1: 1Phase 2: 4
Top Sponsors
- Sun Yat-sen University1
- Sun Yat-Sen University Cancer Center1
- New Approaches to Neuroblastoma Therapy Consortium1
- Memorial Sloan Kettering Cancer Center1
- David Avigan1
Indications
- Cancer5
- Neuroblastoma3
- GM-CSF1
- Relapse Multiple Myeloma1
- Refractory Multiple Myeloma1
Other2 trials
Los Angeles, California1 trial
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Children's Hospital Los Angeles
Phase 2
Boston, Massachusetts1 trial
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
Beth Israel Deaconess Medical Center
Phase 1
New York, New York1 trial
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.